BRN2 is a non-canonical melanoma tumor-suppressor
While the major drivers of melanoma initiation, including activation of NRAS/BRAF and loss of PTEN or CDKN2A , have been identified, the role of key transcription factors that impose altered transcriptional states in response to deregulated signaling is not well understood. The POU domain transcript...
Gespeichert in:
Veröffentlicht in: | Nature communications 2021-06, Vol.12 (1), p.3707-16, Article 3707 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | While the major drivers of melanoma initiation, including activation of NRAS/BRAF and loss of
PTEN
or
CDKN2A
, have been identified, the role of key transcription factors that impose altered transcriptional states in response to deregulated signaling is not well understood. The POU domain transcription factor BRN2 is a key regulator of melanoma invasion, yet its role in melanoma initiation remains unknown. Here, in a
Braf
V600E
Pten
F/+
context, we show that
BRN2
haplo-insufficiency promotes melanoma initiation and metastasis. However, metastatic colonization is less efficient in the absence of Brn2. Mechanistically, BRN2 directly induces
PTEN
expression and in consequence represses PI3K signaling. Moreover, MITF, a BRN2 target, represses
PTEN
transcription. Collectively, our results suggest that on a
PTEN
heterozygous background somatic deletion of one
BRN2
allele and temporal regulation of the other allele elicits melanoma initiation and progression.
The transcription factor BRN2 regulates melanoma migration and invasion, but its role during melanoma initiation is unclear. Here the authors show that BRN2 is a haplo-insufficient tumour suppressor that positively regulates PTEN expression and in the context of BRAF mutation and heterozygous PTEN, BRN2 loss promotes melanoma initiation and progression. |
---|---|
ISSN: | 2041-1723 2041-1723 |
DOI: | 10.1038/s41467-021-23973-5 |